Cargando…

The potential of mRNA expression evaluation in predicting HER2 positivity in gastroesophageal cancer

Gastroesophageal cancer (GEC) is an aggressive disease characterized by a high frequency of metastasis and poor overall survival rates. GEC presents HER2 overexpression in 5 to 25% of tumors eligible for HER2-targeted therapy. HER2 evaluation requires protein levels and copy number alteration analys...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Oliveira, I.M., Nicolau-Neto, P., Fernandes, P.V., Lavigne, T.S., Neves, P.F., Tobar, J.C., Soares-Lima, S.C., Simão, T.A., Pinto, L.F. Ribeiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Divulgação Científica 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668082/ https://www.ncbi.nlm.nih.gov/pubmed/36383805 http://dx.doi.org/10.1590/1414-431X2022e12428

Ejemplares similares

MET overexpression and intratumor heterogeneity in esophageal squamous cell carcinoma
por: Abboud, H.S., et al.
Publicado: (2021)

Her-2 Expression in Gastroesophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2016)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
por: Zhao, Dan, et al.
Publicado: (2019)

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
por: Sigrand, Julie, et al.
Publicado: (2016)

Gene Signal Distribution and HER2 Amplification in Gastroesophageal Cancer
por: Jørgensen, Jan Trøst, et al.
Publicado: (2017)

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
por: Catenacci, D.V.T., et al.
Publicado: (2022)

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma
por: Catenacci, D.V.T., et al.
Publicado: (2021)

Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas
por: Berezowska, Sabina, et al.
Publicado: (2013)

Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers
por: Chuang, Jeremy, et al.
Publicado: (2022)

PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study
por: Beer, Andrea, et al.
Publicado: (2020)

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
por: Van Cutsem, Eric, et al.
Publicado: (2014)

Characterization of the diffuse mucosal associated lymphoid tissue of feline small intestine
por: Roccabianca, P., et al.
Publicado: (2000)

Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas
por: Nielsen, Sofie L., et al.
Publicado: (2017)

Immunotherapy for Gastroesophageal Cancer
por: Goode, Emily F., et al.
Publicado: (2016)

Hydrodynamic simulation of elliptic flow
por: Kolb, P.F., et al.
Publicado: (1999)

HER2 Status in Gastric and Gastroesophageal Junction Cancer Assessed by Local and Central Laboratories: Chinese Results of the HER-EAGLE Study
por: Huang, Dan, et al.
Publicado: (2013)

HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction
por: Ecker, Brett L., et al.
Publicado: (2016)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis
por: Tincknell, Gary, et al.
Publicado: (2022)

Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
por: Kirschbrown, Whitney P., et al.
Publicado: (2019)

Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
por: Dijksterhuis, Willemieke P. M., et al.
Publicado: (2020)

Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population
por: Lago, Nieves Martínez, et al.
Publicado: (2020)

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
por: Esen, Selin Aktürk, et al.
Publicado: (2022)

Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo
por: Kim, Jin-Soo, et al.
Publicado: (2023)

INFLUENCE OF EXERCISE TESTING IN GASTROESOPHAGEAL REFLUX IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE
por: MENDES-FILHO, Antonio Moreira, et al.
Publicado: (2014)

Gastroesophageal Reflux Disease
por: Kulkarni, Gaurav V., et al.
Publicado: (2013)

Characterization of the nasopharyngeal and middle ear microbiota in gastroesophageal reflux-prone versus gastroesophageal reflux non-prone children
por: Boers, Stefan A., et al.
Publicado: (2018)

HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
por: Shan, Ling, et al.
Publicado: (2013)

PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
por: Yokoyama, Daiju, et al.
Publicado: (2021)

HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
por: Li, Weiling, et al.
Publicado: (2022)

Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
por: Radford, Maluki, et al.
Publicado: (2023)

Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population
por: Roy, Partha S, et al.
Publicado: (2019)

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
por: Guarneri, V., et al.
Publicado: (2022)

Evaluation of the Hearing Aid Rehabilitation Questionnaire in Dutch: Examination of its Psychometric Properties and Potential Use as a Screening Instrument
por: Chenault, Michelene N., et al.
Publicado: (2013)

TFF1 hypermethylation and decreased expression in esophageal squamous cell carcinoma and histologically normal tumor surrounding esophageal cells
por: Gonzaga, Isabela Martins, et al.
Publicado: (2017)

An Unusual Course of Metastatic Gastroesophageal Cancer
por: Smith, William H., et al.
Publicado: (2015)

HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma
por: HUANG, JUN-XING, et al.
Publicado: (2013)

Comparison of the Microbiota and Inorganic Anion Content in the Saliva of Patients with Gastroesophageal Reflux Disease and Gastroesophageal Reflux Disease-Free Individuals
por: Ziganshina, Elvira E., et al.
Publicado: (2020)

Protein S-100b as a screening tool for the need of head CT scan after minor head trauma
por: de Figueiredo, LF Poli, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_cemes0c2bifchmnjh06a9lkr46